Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPolar Capital Regulatory News (POLR)

Share Price Information for Polar Capital (POLR)

Share Price is delayed by 15 minutes
Get Live Data
820.00    -11.00 (-1.32%)
Bid:
816.00
Ask:
822.00
Spread: 6.00 (0.735%)
Market Cap: £774.61m
POLR Live PriceLast checked at - London Stock Exchange

Intraday Polar Capital Share Chart

AuM Update

11 Jul 2024 07:00

RNS Number : 9384V
Polar Capital Holdings PLC
11 July 2024
 

11 July 2024 Polar Capital Holdings plc

AuM Update

 

Polar Capital Holdings plc ("Polar Capital" or the "Group"), the specialist active asset management group, today provides its quarterly update of its unaudited statement of its Assets under Management ("AuM").

 

Group AuM (unaudited)

 

Polar Capital reports that as at 30 June 2024 its AuM was £23.5bn compared to £21.9bn at the end of March 2024, an increase of 7% over the quarter. In the quarter, AuM increased by net inflows of £0.6bn and a £1.0bn increase related to market movement and fund performance.

 

AuM movement in three months to 30 June 2024

Open ended

funds

(£m)

Investment

Trusts

(£m)

Segregated mandates

(£m)

Total

(£m)

AuM at 1 April 2024

15,988

5,088

816

21,892

Net flows

719

(78)

3

644

Market movement

and performance

585

391

2

978

Total AuM at 30 June 2024

17,292

5,401

821

23,514

 

 

Gavin Rochussen, Chief Executive, commented:

 

"There has been continued demand for a broad range of our funds during the quarter. Those in net inflows include the Emerging Market Stars (both the UCITS and Emerging Markets Stars 40 Act mutual funds), Asian Stars, Healthcare Opportunities, Global Insurance, Japan Value, Artificial Intelligence and UK Value Opportunities Funds, with combined net inflows of £944m across these funds in the quarter.

 

"Total AuM in the quarter increased by £1.6bn from £21.9bn to £23.5bn, a 7% increase.

 

"The increase in AuM over the quarter of £1.6bn was the result of £644m of net inflows and £978m of fund performance and market movement.

 

"Net inflows in the quarter of £644m were driven in large part by flows into funds managed by the Emerging Markets and Asian Stars team and are a culmination of extensive client engagement over recent years which has led to investor allocations over the two most recent quarters.

 

"There has been further recognition of our Emerging Markets Stars Fund with Polar Capital winning the Emerging Markets Manager of the Year Award in the European Pensions Awards 2024.

 

"Given the strategic focus on growing distribution in the US, it is pleasing that Morningstar have upgraded the Emerging Markets Stars US 40 Act mutual fund from a Bronze to a Silver rating, driven by increased conviction in our investment team.

 

"While the pipeline of investor interest for our fund range remains strong, and it has been pleasing to have two consecutive quarters of net inflows, many investors are still grappling with multiple geopolitical and market risks, and therefore the potential for further redemptions remains.

 

"We remain confident that, with significant fund capacity and improving relative fund performance in our diverse range of differentiated active specialist fund strategies, we are well positioned to perform for our clients and shareholders over the long term."

 

 

 

 

For further information please contact:

 

Polar Capital

Gavin Rochussen (Chief Executive)Samir Ayub (Chief Financial Officer)

+44 (0)20 7227 2700

 

Deutsche Numis - Nomad and Joint Broker

Giles Rolls

Charles Farquhar

 

 

+44 (0)20 7260 1000

 

 

Peel Hunt LLP - Joint Broker

Andrew Buchanan

Sam Milford

 

 

+44 (0)20 3597 8680

Camarco - PR

Ed Gascoigne-Pees

Jennifer Renwick

Phoebe Pugh

+44 (0)20 3757 4995

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDRMMFTMTJBBII
Date   Source Headline
4th Feb 20199:43 amRNSBlock listing Interim Review
1st Feb 201911:41 amRNSTotal Voting Rights
29th Jan 20194:41 pmRNSSecond Price Monitoring Extn
29th Jan 20194:35 pmRNSPrice Monitoring Extension
28th Jan 20195:45 pmRNSIssue of Equity
28th Jan 20195:30 pmRNSDirector/PDMR Shareholding
10th Jan 201910:19 amRNSDirector/PDMR Shareholding
10th Jan 20197:00 amRNSAUM Update
2nd Jan 20199:49 amRNSTotal Voting Rights
12th Dec 20184:00 pmRNSIssue of Equity
27th Nov 20184:40 pmRNSSecond Price Monitoring Extn
27th Nov 20184:35 pmRNSPrice Monitoring Extension
26th Nov 20187:00 amRNSUnaudited Interim Results
22nd Nov 20185:00 pmRNSDirectorate Change
5th Nov 20187:01 amRNSNotice of Results
5th Nov 20187:00 amRNSChange of Nominated Adviser and Broker
1st Nov 20187:00 amRNSTotal Voting Rights
25th Oct 20185:26 pmRNSIssue of Equity
24th Oct 20184:52 pmRNSDirector/PDMR Shareholding
17th Oct 20185:49 pmRNSIssue of Equity
15th Oct 201812:38 pmRNSForm 8.3 - Jardine Lloyd Thompson Group Plc
12th Oct 20182:52 pmRNSForm 8.3 - Jardine Lloyd Thompson Group Plc
11th Oct 20184:42 pmRNSIssue of Equity
11th Oct 20187:01 amRNSCrystallisation of business unit & issue of shares
11th Oct 20187:00 amRNSAUM Update
3rd Oct 201810:24 amRNSForm 8.3 - Jardine Lloyd Thompson Group Plc
19th Sep 201811:52 amRNSForm 8.3 - Jardine Lloyd Thompson Group
18th Sep 201812:02 pmRNSForm 8.3 - Realm Therapeutics PLC
17th Aug 20189:27 amRNSDirectorate Change
6th Aug 20187:00 amRNSBlock listing Interim Review
1st Aug 20187:00 amRNSTotal Voting Rights
31st Jul 20185:57 pmRNSIssue of Equity
31st Jul 201811:29 amRNSDirector/PDMR Shareholding
25th Jul 20183:38 pmRNSDirectorate Change
25th Jul 20183:26 pmRNSResult of AGM
19th Jul 201811:13 amRNSForm 8.3 - Consort Medical Plc
18th Jul 20184:21 pmRNSDirector/PDMR Shareholding
18th Jul 201811:50 amRNSForm 8.3 - Consort Medical Plc
17th Jul 201810:58 amRNSForm 8.3 - Consort Medical Plc
16th Jul 20183:44 pmRNSDirector/PDMR Shareholding
12th Jul 201811:50 amRNSForm 8.3 - Consort Medical Plc
12th Jul 20187:00 amRNSAuM Update
11th Jul 201811:06 amRNSForm 8.3 - Consort Medical Plc
3rd Jul 20186:27 pmRNSHolding(s) in Company
3rd Jul 20186:20 pmRNSIssue of Equity
3rd Jul 201812:07 pmRNSForm 8.3 - Consort Medical Plc
2nd Jul 201810:23 amRNSTotal Voting Rights
29th Jun 20187:00 amRNSBlock Listing Application
28th Jun 20185:55 pmRNSAnnual Financial Report
25th Jun 20187:00 amRNSGroup Audited Results for year ended 31 March 2018

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.